Market Place
Sourcing Support
Spur Presents New Data on Gene Therapy for GBA1 Parkinson
06 Jun 2025 //
GLOBENEWSWIRE
Spur Therapeutics at Citizens JMP 2025 Life Sciences Conference
01 May 2025 //
GLOBENEWSWIRE
Spur Therapeutics to Participate in Upcoming Investor Conferences
19 Nov 2024 //
GLOBENEWSWIRE
Spur Therapeutics To Attend HC Wainwright Neuro Perspectives Conference
20 Jun 2024 //
GLOBENEWSWIRE
Freeline Presents Gaucher, Parkinson`s Data at ASGCT Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
Acquisition of Freeline by Syncona Becomes Effective
20 Feb 2024 //
GLOBENEWSWIRE
Freeline Shareholders Approve Acquisition by Syncona
12 Feb 2024 //
GLOBENEWSWIRE
Syncona to Acquire Freeline Therapeutics
22 Nov 2023 //
GLOBENEWSWIRE
Freeline, facing fading cash runway, mulls buyout by Syncona
19 Oct 2023 //
FIERCE BIOTECH
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
15 Aug 2023 //
GLOBENEWSWIRE
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
08 Aug 2023 //
GLOBENEWSWIRE
Freeline to Participate in Upcoming Investor Conferences
31 Jul 2023 //
GLOBENEWSWIRE
Freeline to Present at 2023 Jefferies Healthcare Conference
02 Jun 2023 //
GLOBENEWSWIRE
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
30 May 2023 //
GLOBENEWSWIRE
Freeline Completes ADS Ratio Change
12 May 2023 //
GLOBENEWSWIRE
Freeline Announces Proposed ADS Ratio Change
21 Apr 2023 //
GLOBENEWSWIRE
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
12 Apr 2023 //
GLOBENEWSWIRE
Viridian Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
GLOBENEWSWIRE
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
28 Mar 2023 //
GLOBENEWSWIRE
Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
10 Feb 2023 //
GLOBENEWSWIRE
Freeline Reports January Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2023 //
GLOBENEWSWIRE
Freeline Receives Approval to Transfer to Nasdaq Capital Market
29 Nov 2022 //
GLOBENEWSWIRE
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing
05 Oct 2022 //
GLOBENEWSWIRE
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190
04 Oct 2022 //
GLOBENEWSWIRE
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing
06 Sep 2022 //
GLOBENEWSWIRE
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
09 Aug 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2022 //
GLOBENEWSWIRE
Freeline: June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
GLOBENEWSWIRE
Freeline to Present New Clinical Data for FLT180a in Hemophilia B
24 Jun 2022 //
GLOBENEWSWIRE
Freeline Initiates Dosing of Second Cohort in Dose Confirmation Trial of FLT180a
14 Jun 2022 //
GLOBENEWSWIRE
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price
03 Jun 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jun 2022 //
GLOBENEWSWIRE
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
10 May 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2022 //
GLOBENEWSWIRE
Freeline To Present at the 25th ASGCT
02 May 2022 //
GLOBENEWSWIRE
Freeline Appoints Paul Schneider as Chief Financial Officer
19 Apr 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2022 //
GLOBENEWSWIRE
Freeline Reports Full Year 2021 Financial Results and Business Highlights
31 Mar 2022 //
GLOBENEWSWIRE
Freeline Shows Updated Development Plan, Timelines for FLT190 in Fabry Disease
24 Mar 2022 //
GLOBENEWSWIRE
Freeline to Participate in Upcoming Investor Conferences
23 Mar 2022 //
GLOBENEWSWIRE
Talis Biomedical Reports Q4 and FY 2021 Financial Results
15 Mar 2022 //
GLOBENEWSWIRE
Freeline says $26.1 M Registered Direct Offering of American Depositary Shares
10 Mar 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2022 //
GLOBENEWSWIRE
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2022 //
GLOBENEWSWIRE
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies
27 Jan 2022 //
GLOBENEWSWIRE
Freeline Announces FDA Clearance of IND Application for FLT201
06 Jan 2022 //
GLOBENEWSWIRE
Freeline Therapeutics to Present FLT180a Data at the 2021 ASH Annual Meeting
04 Nov 2021 //
FREELINE
Freeline Announces ODD for FLT201 for the Treatment of Gaucher Disease
09 Sep 2021 //
GLOBENEWSWIRE
Freeline Appoints Michael J. Parini as Chief Executive Officer
16 Aug 2021 //
GLOBENEWSWIRE
Freeline Provides Executive Leadership Team Update
13 Aug 2021 //
GLOBENEWS WIRE
Freeline Doses 2nd Patient of Ph 1/2 MARVEL-1 Clinical Trial for Fabry Disease
16 Jun 2021 //
GLOBENEWSWIRE
Freeline to Present Data at the 2021 Virtual Congress of European Association
26 Jan 2021 //
GLOBENEWSWIRE
Freeline announces supply agreement for haemophilia B program
23 Sep 2020 //
BIOSPACE
Phase 1/2 gene therapy biotech Freeline Therapeutics files for a $100 M US IPO
17 Jul 2020 //
RENAISSANCECAPITAL
Freeline receives Orphan Drug Designation from the European Commission
10 Mar 2020 //
PHARMIWEB
